Brookline Capital Management Estimates CRBU Q1 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Analysts at Brookline Capital Management issued their Q1 2025 earnings estimates for Caribou Biosciences in a research note issued to investors on Tuesday, March 11th. Brookline Capital Management analyst L. Cann forecasts that the company will post earnings of ($0.40) per share for the quarter. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share. Brookline Capital Management also issued estimates for Caribou Biosciences' Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.15) EPS, FY2026 earnings at ($2.24) EPS, FY2027 earnings at ($3.86) EPS and FY2028 earnings at ($1.74) EPS.

Several other equities analysts have also issued reports on CRBU. Bank of America cut their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Citigroup cut their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating on the stock in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $10.33.

Caribou Biosciences Stock Up 1.0 %

CRBU stock traded up $0.01 during trading on Thursday, hitting $1.02. 986,362 shares of the company's stock traded hands, compared to its average volume of 1,603,014. The firm has a market capitalization of $94.87 million, a P/E ratio of -0.62 and a beta of 2.34. The business has a fifty day simple moving average of $1.37 and a two-hundred day simple moving average of $1.77. Caribou Biosciences has a 1 year low of $0.98 and a 1 year high of $5.77.

Remove Ads

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million.

Hedge Funds Weigh In On Caribou Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Erste Asset Management GmbH purchased a new position in Caribou Biosciences in the third quarter worth $28,000. Centric Wealth Management purchased a new position in Caribou Biosciences in the fourth quarter worth $27,000. Intech Investment Management LLC purchased a new position in Caribou Biosciences in the third quarter worth $43,000. Russell Investments Group Ltd. grew its holdings in Caribou Biosciences by 859.0% in the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company's stock worth $38,000 after purchasing an additional 21,416 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in Caribou Biosciences by 60.0% in the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock worth $39,000 after purchasing an additional 9,148 shares during the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.